Company: SHPH
Filing Date: 2025-02-13
Form Type: S-1
Source: 0001493152-25-006202
Chunk: 240

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-13
Form: S-1
Chunk 240
---
, the Company’s then CFO
was awarded 12,500
restricted stock units (“RSUs”), with a value of $41,840,
with such RSUs vesting in full as of the date of issuance. Each RSU represents the right to receive one share of SHPH common
stock.

On June 13, 2024, the Company’s newly appointed CFO was awarded 28,455restricted stock units (“RSUs”), with a value of $ 100,000, with such RSUs vesting annually in three equal installments following the date of issuance. Each RSU represents the right to receive one share of SHPH common stock.

Alto Opportunity Master Fund, SPC

On July 12, 2024, the Company informed the Investor in the Alto Convertible Note that the Company’s expected restatement of its consolidated financial statements for the years ended December 31, 2022 and 2023 constituted an event of default under the terms of the Alto Convertible Note. On August 6, 2024, the Company paid $ 600,000to the Investor, which funds will be held as collateral to the balance owed under the Alto Convertible Note, and received a waiver from the Investor related to the default.

Alliance Global Partners

On July 30, 2024, the Company
engaged A.G.P./Alliance Global Partners (“AGP”) to serve as exclusive underwriter, placement agent or advisor in
any public or private offering or financing (as defined, the “Offering”) of up to $10million.

| F-46 |

<div align='center'>Up to [*] Shares of Common Stock

Up to [*] Pre-Funded Warrants to Purchase up to[*] Shares of Common Stock

Up to [*] Shares of Common Stock Underlying such Pre-Funded Warrants

SHUTTLE PHARMACEUTICALS HOLDINGS, INC.

WestPark Capital, Inc.

PROSPECTUS

__, 2025</div>

<div align='center'>PART II</div>

INFORMATION NOT REQUIRED IN THE PROSPECTUS

| ITEM 
 13.  | OTHER                                 
 EXPENSES OF ISSUANCE AND DISTRIBUTION |

The following table sets forth the estimated costs and expenses payable by the registrant expected to be incurred in connection with the sale and distribution of the securities being registered hereby (other than the Underwriter 4% cash fees and an up to $45,000 non-accountable expense allowance).